Thursday, May 24, 2018

Hadley Logo (Go back to homepage)

Did you know that Hadley Institute for the Blind and Visually Impaired offers free classes for visually impaired individuals and their families?  Click HERE to learn more!

Fun Fact:  Did you know that Dr Steven Brown's grandfather was the co-founder of Hadley?

From their website:


When he lost his sight at age 55, William A. Hadley faced many challenges. A former high school teacher, Mr. Hadley taught himself braille so that he could continue to enjoy reading, but was frustrated to find that there were few educational opportunities for blind individuals.
Mr. Hadley's dream was to help others acquire communication skills that foster independence. Together with Dr. E.V.L. Brown, an ophthalmologist and neighbor, Mr. Hadley conceived the idea of teaching braille by mail. In 1920, the school opened to its first student. When Mr. Hadley mailed the braille course to this Kansas woman desperate to continue reading, one wonders if he ever imagined the eventual result: a school that would become the single largest worldwide educator of blind people.
When Mr. Hadley died in 1941, the school had 800 students enrolled. Today, Hadley has an annual enrollment of more than 10,000 students from all 50 states and in 100 countries.
We at Hadley Institute for the Blind and Visually Impaired remain committed to realizing our founder's dream for decades to come.

Dr Gorla presented at the Annual Illinois Society of Eye Physicians & Surgeons/Chicago Ophthalmological joint Meeting.  He presented a lecture entitled: “Lowering IOP with Punctal Plugs and Ocular Implants” which discussed new glaucoma treatments in the pharmaceutical pipeline. 

Tuesday, April 10, 2018

Dr Steven Brown, Dr Adam Breunig & Dr Jennifer Rossen presented a poster at the American Society of Cataract and Refractive Surgery Annual Meeting in Washington DC entitled:
“Dropless Cataract Sugery: One Surgeon’s Experience”

Saturday, January 27, 2018

Dr Gorla presented “MIGS Update” & “MIGS vs. Traditional Surgery - Are we progressing?”  Lecture at January's Loyola Chicago Subspecialty Lecture Series

To learn more about MIGS, click HERE

Saturday, September 30, 2017

Image may contain: 2 people, people smilingDr Gorla served as a panelist at the 10th Annual Glaucoma/Cataract Symposium which was hosted by Loyola University Chicago Department of Ophthalmology.  

Monday, July 31, 2017

Dr Brown presented the Honorary Al Ruedemann Lecture at the 2017 American Eye Study Club Annual Meeting

Dr Brown provided a history of the the AESC along with findings of a recent research project he has been working on.  It was an honor for him to present at the Annual Meeting

Friday, June 30, 2017

Published Article in Glaucoma Today (May/June 2017)


A 70-year-old woman was referred to our office as a glaucoma suspect in the setting of recurrent herpes simplex virus (HSV) epithelial and stromal keratitis of the right eye. The patient had no history of associated uveitis. Primary angle closure was suspected, and she underwent bilateral laser peripheral iridotomies (LPIs). Her medications at presentation included latanoprost at bedtime, a fixed combination of dorzolamide and timolol twice daily, brimonidine twice daily, trifluridine of varying frequency, frequent loteprednol tapers for intermittent corneal stromal involvement, and oral acyclovir 800 mg three times daily.
Although the LPIs succeeded in opening the angles, IOP remained in the mid-20s in the right eye. Optical coherence tomography of the retinal nerve fiber layer showed thinning of the right optic nerve compared to the left, with a corresponding nasal step on the visual field. Because the patient was overwhelmed by the drop regimen and we were concerned about corneal toxicity, we performed selective laser trabeculoplasty (SLT) in an attempt to reduce the medication burden. Unfortunately, the IOP remained unchanged.
Subsequently, the patient underwent trabeculectomy with mitomycin C in the right eye. Approximately 6 months postoperatively, she underwent a full-thickness corneal transplant in the same eye. Ten years later, she maintains a BCVA of 20/40 and an IOP in the upper teens on no glaucoma drops in the right eye. She continues to use loteprednol etabonate ophthalmic ointment 0.5% (Lotemax; Bausch + Lomb) once daily for rejection prophylaxis and takes oral acyclovir 400 mg twice daily to reduce the risk of recurrent HSV.